MIM
CRSP icon

MetLife Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

MetLife Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.96M Buy
54,243
+4,607
+9% +$243K 0.01% 922
2026
Q1 		$2.36M Buy
49,636
+1,625
+3% +$85.7K 0.01% 969
2025
Q4 		$2.52M Sell
48,011
-224
-0.5% -$13.4K 0.01% 958
2025
Q3 		$3.13M Sell
48,235
-1,104
-2% -$63.4K 0.02% 867
2025
Q2 		$2.4M Buy
+49,339
New +$1.91M 0.01% 921

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MetLife Investment Management's CRSP Position: Q2 2026 in Review

MetLife Investment Management increased its CRISPR Therapeutics (CRSP) stake by 9.3% in Q2 2026, buying an estimated $243K and bringing the position to 54,243 shares worth $2.96M. The position accounts for 0.01% of the portfolio, ranked #922.

MetLife Investment Management first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.13M in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • MetLife Investment Management held 54,243 shares of CRISPR Therapeutics worth $2.96M as of Q2 2026.
  • MetLife Investment Management bought 4,607 CRISPR Therapeutics shares in Q2 2026, an estimated $243K.
  • CRISPR Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #922 holding.
  • MetLife Investment Management first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • MetLife Investment Management's CRISPR Therapeutics position peaked at $3.13M in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.